Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 3:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 496 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 0.9% Normal Saline (0.9% Sodium Chloride) injection Clear all

Conditions: COVID-19-Induced Parosmia
Interventions: Stellate Ganglion Block, Placebo Sham Injection; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Intermittent Claudication
Interventions: Trans sodium crocetinate (TSC), 0.9% normal saline; Drug
Lead sponsor: Diffusion Pharmaceuticals Inc; Industry
Eligibility: 40 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 7
States / cities: Birmingham, Alabama • Santa Rosa, California • Stanford, California + 4 more

Conditions: Carcinoid Syndrome
Interventions: Lanreotide, Placebo; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 16
States / cities: Los Angeles, California • Stanford, California • West Hollywood, California + 11 more

Conditions: Osteoarthritis
Interventions: Monovisc®, Saline; Device · Other
Lead sponsor: Anika Therapeutics, Inc.; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 30
States / cities: Hoover, Alabama • Mesa, Arizona • Phoenix, Arizona + 27 more

Conditions: Respiratory Syncytial Virus
Interventions: Placebo, mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 3,317 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 62
States / cities: Birmingham, Alabama • Tucson, Arizona • Garden Grove, California + 51 more

Conditions: Hereditary Hemochromatosis
Interventions: LJPC-401, Placebo; Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 18
States / cities: North Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Lumbar Disc Disease
Interventions: BRTX-100, Saline; Biological · Drug
Lead sponsor: BioRestorative Therapies; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Santa Monica, California • Walnut Creek, California + 15 more

Conditions: Meniscus Tear
Interventions: AM3101, Saline Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 40 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Cincinnati, Ohio • Cleveland, Ohio • Portland, Oregon

Conditions: SARS-CoV-2
Interventions: mRNA-1273, Placebo, mRNA-1273.222; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 12 Years to 18 Years
Enrollment: 4,328 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 48
States / cities: Banning, California • La Mesa, California • Lake Worth, Florida + 41 more

Conditions: Bilateral Primary Osteoarthritis of Knee
Interventions: Autologous Bone Marrow Aspirate Concentrate, Sterile saline; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Osteoarthritis of the Hand
Interventions: AMPION™, Saline; Biological
Lead sponsor: Ampio Pharmaceuticals. Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Intracranial Atherosclerosis
Interventions: Feraheme; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Snakebite, Envenoming, Snake
Interventions: Varespladib intravenous form, varespladib-methyl- oral form, Placebo intravenous form, Placebo - oral form; Drug
Lead sponsor: Ophirex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Phoenix, Arizona • Tucson, Arizona • Palm Springs, California + 7 more

Conditions: Antibiotic Prophylaxis Surgery
Interventions: CeFAZolin 1000 MG, Saline (0.9%, sterile, for infusion); Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Somerset, New Jersey

Conditions: Spasticity
Interventions: intramuscular Botox versus oral baclofen; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Fasciitis, Plantar
Interventions: Micronized dHACM, Saline Injection; Other · Drug
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 21 Years to 79 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 17
States / cities: Tucson, Arizona • Carlsbad, California • Carmichael, California + 14 more

Conditions: Healthy
Interventions: Saline, Glucagon, Placebo, Atenolol; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: SARS-CoV-2
Interventions: mRNA-1273.214, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 2 Months to 6 Months
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 39
States / cities: Bessemer, Alabama • Birmingham, Alabama • Tucson, Arizona + 34 more

Conditions: Multiple Sclerosis
Interventions: Tysabri; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Clostridoides Difficile Associated Disease
Interventions: C. difficile vaccine (previously studied formulation)., C. difficile vaccine formulation 1., C. difficile vaccine formulation 2., C. difficile vaccine formulation 3., Saline Placebo.; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 936 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2031
U.S. locations: 23
States / cities: Phoenix, Arizona • Anaheim, California • Doral, Florida + 17 more

Conditions: Iron Deficiency Anemia
Interventions: Ferumoxytol, FCM; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 100
States / cities: Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 83 more

Conditions: Healthy
Interventions: MVA-BN-Filo, Ad26. ZEBOV, Placebo; Biological · Other
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Escherichia Infection
Interventions: B7A (ETEC challenge strain), CssBA, dmLT, Placebo; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: COVID-19
Interventions: VYD2311-SD, VYD2311-MD, Placebo; Drug
Lead sponsor: Invivyd, Inc.; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 1,770 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 20
States / cities: Long Beach, California • San Diego, California • Orlando, Florida + 17 more

Search by objective public record fields.

Stellate Ganglion Block for COVID-induced Parosmia

Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

Safety and Effectiveness of Monovisc® Injection for Osteoarthritis of the Knee

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age

A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis

A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

Use of Autologous Bone Marrow Aspirate Concentrate in Painful Knee Osteoarthritis

AP-011 Study to Evaluate the Safety of a Single Intra-articular Injection of Ampion™ for Arthritis of the Basal Thumb Joint

Predicting Stroke Risk in ICAD With Novel MRI

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)

Efficacy and Safety of Intraosseous Antibiotic Prophylaxis in Total Hip Replacement

Botox vs. Baclofen for Upper Limb Spasticity

Micronized dHACM Injectable for the Treatment of Plantar Fasciitis

Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones

Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants

Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults

A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults

Study of VYD2311 for the Prevention of COVID-19